Reply to Kim et al. Acute Hemorrhagic Encephalomyelitis in the Context of MOG Antibody-Associated Disease. Comment on “Chen et al. Rapid Progressive Fatal Acute Hemorrhagic Encephalomyelitis. Diagnostics 2023, 13, 2481”
1
Department of Radiology, Division of Neuroradiology, Taichung Veterans General Hospital, Taichung 40705, Taiwan
2
School of Medicine, National Yang-Ming Chiao Tung University, Taipei 112304, Taiwan
3
Department of Neurology, Neurological Institute, Taichung Veterans General Hospital, Taichung 40705, Taiwan
4
Dementia and Parkinson’s Disease Integrated Center, Taichung Veterans General Hospital, Taichung 40705, Taiwan
5
Center for Geriatrics and Gerontology, Taichung Veterans General Hospital, Taichung 40705, Taiwan
*
Author to whom correspondence should be addressed.
Diagnostics 2023, 13(23), 3549; https://doi.org/10.3390/diagnostics13233549
Submission received: 16 October 2023
/
Accepted: 8 November 2023
/
Published: 28 November 2023
(This article belongs to the Special Issue Advances in Brain Magnetic Resonance Imaging for Human Disorders)
We want to express our appreciation for the insightful comments [1] that you made on our recent article, which discussed a case of acute hemorrhagic encephalomyelitis (AHEM) in a middle-aged male patient. Your analysis provided a valuable perspective on this complex clinical scenario.
Your suggestion that AHEM might be linked to myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is intriguing. We also acknowledge your observation that certain clinical features of AHEM overlap with those of MOGAD, and the similarities between the brain MRI findings [1] are undeniably thought-provoking. We agree that this observation warrants further investigation.
Regarding MOG antibody testing, to clarify, we conducted this test, and the results were negative in our patient. We apologize for any confusion that arose from the omission of this critical detail from our original article. Serum and/or cerebrospinal fluid (CSF) autoantibody tests were performed using a commercial cell-based indirect immunofluorescence assay (Uni Pharma Co., Ltd., Taipei, Taiwan). CSF and serum samples were tested for the presence of autoantibodies against NMDAR, AMPAR1, AMPAR2, CASPR2, LGI1, and GABAbR; the serum sample was also examined for the presence of autoantibodies against AQP4 and MOG. Both CSF and serum tested negative for all the above-mentioned antibodies.
In conclusion, we appreciate your comments and commitment to advancing our understanding of AHEM. Your insights will undoubtedly influence the direction of our future research. We hope that ongoing studies will further outline the intricate relationship between AHEM and MOGAD.
Once again, thank you once for your engagement with our work and enriching the discussion.
Author Contributions
H.-C.C. and T.-B.C. wrote the reply. All authors have read and agreed to the published version of the manuscript.
Conflicts of Interest
The authors declare no conflict of interest.
Reference
- Kim, S.; Eun, M.-Y.; Lee, J.-J.; Seok, H.Y. Acute Hemorrhagic Encephalomyelitis in the Context of MOG Antibody-Associated Disease. Comment on Chen et al. Rapid Progressive Fatal Acute Hemorrhagic Encephalomyelitis. Diagnostics 2023, 13, 2481. Diagnostics 2023, 13, 3148. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Chen, H.-C.; Chen, T.-B. Reply to Kim et al. Acute Hemorrhagic Encephalomyelitis in the Context of MOG Antibody-Associated Disease. Comment on “Chen et al. Rapid Progressive Fatal Acute Hemorrhagic Encephalomyelitis. Diagnostics 2023, 13, 2481”. Diagnostics 2023, 13, 3549. https://doi.org/10.3390/diagnostics13233549
AMA Style
Chen H-C, Chen T-B. Reply to Kim et al. Acute Hemorrhagic Encephalomyelitis in the Context of MOG Antibody-Associated Disease. Comment on “Chen et al. Rapid Progressive Fatal Acute Hemorrhagic Encephalomyelitis. Diagnostics 2023, 13, 2481”. Diagnostics. 2023; 13(23):3549. https://doi.org/10.3390/diagnostics13233549
Chicago/Turabian StyleChen, Hung-Chieh, and Ting-Bin Chen. 2023. "Reply to Kim et al. Acute Hemorrhagic Encephalomyelitis in the Context of MOG Antibody-Associated Disease. Comment on “Chen et al. Rapid Progressive Fatal Acute Hemorrhagic Encephalomyelitis. Diagnostics 2023, 13, 2481”" Diagnostics 13, no. 23: 3549. https://doi.org/10.3390/diagnostics13233549
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
